

NEW PATENT APPLICATION

Inventors: Auf Der Maur et al.

For: Intrabodies With Defined Framework That is Stable in a Reducing Environment and Applications Thereof


Attorney Docket No: 27656/37021

Mailing Certification for: Sequence Listing and Computer Disk Containing the Sequence Listing for the Application and Statement Under 37 C.F.R. §1.821(f)

"EXPRESS MAIL" mailing label No. EM578443637US


Date of Deposit: December 28, 2000

I hereby certify that this paper (or fee) is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.


Richard Zimmermann

Statement Under 37 C.F.R. §1.821(f)

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.


Jeffrey S. Sharp
Reg. No. 31,879

SEQUENCE LISTING

<110> Auf der Maur, Adrian
Barberis, Alcide
Escher, Dominik

<120> INTRABODIES WITH DEFINED FRAMEWORK THAT IS STABLE IN A
REDUCING ENVIRONMENT AND APPLICATIONS THEREOF

<130> 27656/37021

<140>
<141>

<150> 09/529,307
<151> 2000-04-11

<150> PCT/IB00/00218
<151> 2000-03-01

<150> PCT/IB99/02054
<151> 1999-12-28

<160> 11

<170> PatentIn Ver. 2.1

<210> 1
<211> 252
<212> PRT
<213> Mus musculus

<220>
<221> CHAIN
<222> (1)..(114)
<223> Variable light chain

<220>
<221> CHAIN
<222> (135)..(247)
<223> Variable heavy chain

<220>
<221> REPEAT
<222> (115)..(134)
<223> Glycine Serine Linker

<220>
<221> PEPTIDE
<222> (248)..(252)
<223> His Tag

<220>
<221> DOMAIN

<222> (27)..(39)

<223> CDR 1 VL

<220>

<221> DOMAIN

<222> (95)..(103)

<223> CDR 3 VL

<220>

<221> DOMAIN

<222> (165)..(169)

<223> CDR 1 VH

<220>

<221> DOMAIN

<222> (184)..(198)

<223> CDR 2 H

<220>

<221> DOMAIN

<222> (232)..(236)

<223> CDR 3 VH

<400> 1

Met Gly Pro Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
1 5 10 15

Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala
20 25 30

Val Thr Thr Ser Asn Tyr Ala Ser Trp Val Gln Lys Lys Pro Gly Lys
35 40 45

Arg Phe Lys Gly Leu Ile Gly Gly Thr Asn Asn Arg Ala Pro Gly Val
50 55 60

Pro Ser Arg Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr
65 70 75 80

Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Ala Leu
85 90 95

Trp Tyr Ser Asn His Trp Val Phe Gly Gln Gly Thr Lys Val Glu Leu
100 105 110

Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125

Ser Ser Gly Gly Gly Ser Glu Val Lys Leu Leu Glu Ser Gly Gly Gly
130 135 140

Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Val Ser Gly
145 150 155 160

bioRxiv preprint doi: <https://doi.org/10.1101/201709.000000>; this version posted September 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Phe	Ser	Leu	Thr	Asp	Tyr	Gly	Val	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly
				165					170					175	
Arg	Gly	Leu	Glu	Trp	Ile	Gly	Val	Ile	Trp	Gly	Asp	Gly	Ile	Thr	Asp
		180						185					190		
Tyr	Asn	Ser	Ala	Leu	Lys	Asp	Arg	Phe	Ile	Ile	Ser	Lys	Asp	Asp	Cys
		195					200					205			
Glu	Asn	Ser	Val	Tyr	Leu	Gln	Met	Ser	Lys	Val	Arg	Ser	Asp	Asp	Thr
	210					215					220				
Ala	Leu	Tyr	Tyr	Cys	Val	Thr	Gly	Leu	Phe	Asp	Tyr	Trp	Gly	Gln	Gly
225					230					235					240
Thr	Leu	Val	Thr	Val	Ser	Ser	His	His	His	His	His				
				245					250						

<210> 2
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: synthetic peptide

<400> 2
 Gly Leu Phe Asp Tyr
 1 5

<210> 3
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: synthetic peptide

<400> 3
 Ala Gly Leu Phe Asp Tyr
 1 5

<210> 4
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: synthetic peptide Glycine Serine Linker

<400> 4

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
1 5 10 15

Gly Gly Gly Ser
20

<210> 5

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR upstream
Primer

<400> 5

ccatggggccc aagctttgca aagatggata aag 33

<210> 6

<211> 85

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
peptide linker

<400> 6

tttggggcccg aagaaccgcc accaccagaa ccgcctccac cagagccacc accaccaggc 60
ctgatctctt tttttgggtt tggtg 85

<210> 7

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
peptide linker

<400> 7

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10

<210> 8

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR upstream
primer

<400> 8

catgccatgg ttcctcaaca gcagcaaatg caac

34

<210> 9

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR downstream
primer

<400> 9

catgccatgg cgctagccaa agcttggatt tttctcagg

39

<210> 10

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 10

cctatgactc atccagttat gactcatcg

29

<210> 11

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 11

tcgacgatga gtcataactg gatgagtcac aggcacg

37